Volume 85 Issue 14 | p. 26 | Concentrates
Issue Date: April 2, 2007

Eye Company Formed

Department: Business

Acuity Pharmaceuticals and Froptix have agreed to merge with eXegenics, a publicly traded company with no current active operations, to form a new firm, Opko, listed on the American Stock Exchange. Acuity and Froptix both have drug discovery efforts in eye disease. Acuity has two drugs in development: bevasiranib, in Phase II trials for wet macular degeneration, and a product in Phase I trials for conjunctivitis. Froptix has a range of small molecules in preclinical studies. Opko has received a $12 million credit line from the Frost Group to help fund a Phase III trial of bevasiranib.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment